Immunohistochemical Profile of Er, Pr, Her2, and Ki-67 In Breast Cancer Patients
Abstract
Breast cancer remains one of the leading causes of cancer-related mortality among women worldwide, with hormonal factors playing a critical role in tumor development and progression. This study aims to describe the immunohistochemical profile of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and Ki-67 in breast cancer patients at MRCCC Siloam Semanggi Hospital in 2022. A retrospective descriptive study was conducted using a total sampling of anatomical pathology archives, comprising 316 breast cancer cases. The most common age group was 40–49 years. ER positivity was observed in 229 patients (72.5%), while PR positivity was found in 183 patients (57.9%). HER2 overexpression (3+) was identified in 75 patients (23.7%); cases with equivocal HER2 (2+) required confirmation by in situ hybridization. High proliferative activity, indicated by Ki-67 ≥20%, was present in 262 patients (82.9%). These findings indicate a predominance of hormone receptor–positive tumors with high proliferative indices, highlighting the importance of immunohistochemical profiling in guiding prognosis assessment, therapeutic decision-making, and selection of targeted and systemic treatments in breast cancer management.
Keywords: Breast Cancer, Immunohistochemistry, Estrogen Receptor (ER), HER2, Ki-67
Full Text:
PDFReferences
Ahmed, Rashed. 2024. “Immunoglobulins: Structure, Function, and Therapeutic Applications in Immune Response.” RADINKA JOURNAL OF HEALTH SCIENCE 2(2):220–25. doi: 10.56778/RJHS.V2I2.359.
Ahn, Soomin, Ji Won Woo, Kyoungyul Lee, and So Yeon Park. 2020. “HER2 Status in Breast Cancer: Changes in Guidelines and Complicating Factors for Interpretation.” Journal of Pathology and Translational Medicine 54(1):34–44.
Van Asten, Kathleen, Laurence Slembrouck, Siel Olbrecht, Lynn Jongen, Olivier Brouckaert, Hans Wildiers, Giuseppe Floris, Erik Van Limbergen, Caroline Weltens, and Ann Smeets. 2019. “Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer.” The Oncologist 24(2):165–71.
Bellanger, Martine, Nur Zeinomar, Parisa Tehranifar, and Mary Beth Terry. 2018. “Are Global Breast Cancer Incidence and Mortality Patterns Related to Country-Specific Economic Development and Prevention Strategies?” Journal of Global Oncology (4):1–16. doi: 10.1200/jgo.17.00207.
Davey, Matthew G., Sean O. Hynes, Michael J. Kerin, Nicola Miller, and Aoife J. Lowery. 2021. “Ki-67 as a Prognostic Biomarker in Invasive Breast Cancer.” Cancers 13(17):4455.
DeSantis, Carol E., Freddie Bray, Jacques Ferlay, Joannie Lortet-Tieulent, Benjamin O. Anderson, and Ahmedin Jemal. 2015. “International Variation in Female Breast Cancer Incidence and Mortality Rates.” Cancer Epidemiology, Biomarkers & Prevention 24(10):1495–1506.
Ferlay, Jacques, Murielle Colombet, Isabelle Soerjomataram, Donald M. Parkin, Marion Piñeros, Ariana Znaor, and Freddie Bray. 2021. “Cancer Statistics for the Year 2020: An Overview.” International Journal of Cancer 149(4):778–89. doi: 10.1002/ijc.33588.
Ferrando-Díez, Angelica, Eudald Felip, Anna Pous, Milana Bergamino Sirven, and Mireia Margelí. 2022. “Targeted Therapeutic Options and Future Perspectives for HER2-Positive Breast Cancer.” Cancers 14(14):3305.
Finkelman, Brian S., Huina Zhang, David G. Hicks, and Bradley M. Turner. 2023. “The Evolution of Ki-67 and Breast Carcinoma: Past Observations, Present Directions, and Future Considerations.” Cancers 15(3):808.
Fu, Mengxia, Zhiming Peng, Min Wu, Dapeng Lv, Yanping Li, and Shuzhen Lyu. 2025. “Current and Future Burden of Breast Cancer in Asia: A GLOBOCAN Data Analysis for 2022 and 2050.” The Breast 79:103835.
Fujiki, Yoshitaka, Masahiro Kashiwaba, Mutsumi Sato, Junko Kawano, Megumi Teraoka, Shuichi Kanemitsu, Yoshiaki Rai, Tetsuhiko Taira, Yoshiaki Sagara, Yasuyo Ohi, Uiree Jo, Young-Won Lee, Sae Byul Lee, Gyungyub Gong, Young Kee Shin, Mi Jeong Kwon, and Yasuaki Sagara. 2024. “Long-Term Prognostic Value of the GenesWell BCT Score in Asian Women with Hormone Receptor-Positive/HER2-Negative Early Breast Cancer.” Breast Cancer 31(1):31–41. doi: 10.1007/s12282-023-01509-7.
Honma, Naoko, Masayuki Yoshida, Keiichi Kinowaki, Rie Horii, Yuka Katsurada, Yuya Murata, Ai Shimizu, Yuko Tanabe, Chikako Yamauchi, Yutaka Yamamoto, Hiroji Iwata, and Shigehira Saji. 2024. “The Japanese Breast Cancer Society Clinical Practice Guidelines for Pathological Diagnosis of Breast Cancer, 2022 Edition.” Breast Cancer 31(1):8–15. doi: 10.1007/s12282-023-01518-6.
Islami, Farhad, Jordan Baeker Bispo, Hyunjung Lee, Daniel Wiese, K. Robin Yabroff, Priti Bandi, Kirsten Sloan, Alpa V Patel, Elvan C. Daniels, Arif H. Kamal, Carmen E. Guerra, William L. Dahut, and Ahmedin Jemal. 2024. “American Cancer Society’s Report on the Status of Cancer Disparities in the United States, 2023.” CA: A Cancer Journal for Clinicians 74(2):136–66. doi: 10.3322/caac.21812.
Kamranzadeh, Hosein, Reza Manouchehri Ardekani, Amir Kasaeian, Sanambar Sadighi, Somaye Maghsudi, Issa Jahanzad, and Nasrollah Maleki. 2019. “Association between Ki-67 Expression and Clinicopathological Features in Prognosis of Breast Cancer: A Retrospective Cohort Study.” Journal of Research in Medical Sciences 24(1):30.
Loganathan, Tamizhini, and C. George Priya Doss. 2025. “Computational Molecular Insights into Ibrutinib as a Potent Inhibitor of HER2-L755S Mutant in Breast Cancer: Gene Expression Studies, Virtual Screening, Docking, and Molecular Dynamics Analysis.” Frontiers in Molecular Biosciences 12:1510896.
Luengo, Monserrat Hernández, Celia Álvarez-Bueno, Diana P. Pozuelo-Carrascosa, Carlos Berlanga-Macías, Vicente Martínez-Vizcaíno, and Blanca Notario-Pacheco. 2019. “Relationship between Breast Feeding and Motor Development in Children: Protocol for a Systematic Review and Meta-Analysis.” BMJ Open 9(9):e029063.
Ma, Qin, Yao-Bang Liu, Tong She, and Xin-Lan Liu. 2024. “The Role of Ki-67 in HR+/HER2- Breast Cancer: A Real-World Study of 956 Patients.” Breast Cancer: Targets and Therapy Volume 16:117–26. doi: 10.2147/bctt.s451617.
Magaki, Shino, Seyed A. Hojat, Bowen Wei, Alexandra So, and William H. Yong. 2019. “An Introduction to the Performance of Immunohistochemistry.” Methods in Molecular Biology (Clifton, N.J.) 1897:289. doi: 10.1007/978-1-4939-8935-5_25.
Maranta, Angela Fischer, Simon Broder, Constanze Fritzsche, Michael Knauer, Beat Thürlimann, Wolfram Jochum, and Thomas Ruhstaller. 2020. “Do YOU Know the Ki-67 Index of Your Breast Cancer Patients? Knowledge of Your Institution’s Ki-67 Index Distribution and Its Robustness Is Essential for Decision-Making in Early Breast Cancer.” The Breast 51:120–26.
Osborne, Augustus, Qorinah Estiningtyas Sakilah Adnani, and Bright Opoku Ahinkorah. 2025. “Breast Cancer Incidence in Indonesia: A Sex-Disaggregated Analysis Using WHO Health Equity Assessment Toolkit Data.” BMC Cancer 25(1). doi: 10.1186/S12885-025-14332-4.
Penault-Llorca, Frederique, and Nina Radosevic-Robin. 2017. “Ki67 Assessment in Breast Cancer: An Update.” Pathology 49(2):166–71.
Rajc, Jasmina, Irena Fröhlich, Milanka Mrčela, Ilijan Tomaš, and Josipa Flam. 2018. “Prognostic Impact of Low Estrogen and Progesterone Positivity in Luminal B (Her2 Negative) Breast Cancer.” Acta Clinica Croatica 57(3.):425–33.
Rodrigues, Ilda, Rute Fernandes, Ana Ferreira, Deolinda Pereira, Rúben Fernandes, Raquel Soares, and Carla Luís. 2024. “Is Progesterone Receptor a Neglected Feature in Breast Cancer? A Retrospective Study Analysing the Clinicopathological Characteristics of Breast Cancer Based on Progesterone Receptor Status.” Clinical Breast Cancer.
Sajjadi, Elham, Konstantinos Venetis, Mariia Ivanova, and Nicola Fusco. 2022. “Improving HER2 Testing Reproducibility in HER2-Low Breast Cancer.” Cancer Drug Resistance 5(4):882.
Schusterman II, M. Asher, and Robert D. Rehnke. 2023. “The LOTUS Pre-Pectoral Breast.” Prepectoral Breast Reconstruction: Current Trends and Techniques 259.
Smolarz, Beata, Anna Zadrożna Nowak, and Hanna Romanowicz. 2022. “Breast Cancer—Epidemiology, Classification, Pathogenesis and Treatment (Review of Literature).” Cancers 14(10):2569.
Sung, Hyuna, Jacques Ferlay, Rebecca L. Siegel, Mathieu Laversanne, Isabelle Soerjomataram, Ahmedin Jemal, and Freddie Bray. 2021. “Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.” CA: A Cancer Journal for Clinicians 71(3):209–49. doi: 10.3322/caac.21660.
Wolff, Antonio C., Mark R. Somerfield, Mitchell Dowsett, M. Elizabeth H. Hammond, Daniel F. Hayes, Lisa M. McShane, Thomas J. Saphner, Patricia A. Spears, and Kimberly H. Allison. 2023. “Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology–College of American Pathologists Guideline Update.” Archives of Pathology & Laboratory Medicine 147(9):993–1000.
Yaneva, Galina, Tsonka Dimitrova, Dobri Ivanov, Gergana Ingilizova, and Sergei Slavov. 2022. “Immunohistochemical Marker Patterns in Female Breast Cancer.” Open Access Macedonian Journal of Medical Sciences 10(B):1595–1601.
Zagami, Paola, and Lisa Anne Carey. 2022. “Triple Negative Breast Cancer: Pitfalls and Progress.” NPJ Breast Cancer 8(1):95.
Zaha, Dana Carmen. 2014. “Significance of Immunohistochemistry in Breast Cancer.” World Journal of Clinical Oncology 5(3):382.
DOI: http://dx.doi.org/10.30829/contagion.v7i3.25681
Refbacks
- There are currently no refbacks.
Copyright (c) 2026 Marliana Nurprilinda, Erida Manalu, Tiroy Sari B. Simanjuntak, Reinhard Christovel Andreas
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
